Compare Adaptive Biotechnologies Corp (ADPT) vs American Well Corp (AMWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American Well Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.17 (market cap $4.04B), while American Well Corp trades at $12.76 (market cap $220.94M). The key difference: Adaptive Biotechnologies Corp is far larger — about 18.3× American Well Corp's market cap. Which is the better fit depends on your goals.
| ADPT | AMWL | |
|---|---|---|
Market Cap | $4.04B | $220.94M |
Sector | Health | Health |
52-Week High | $25.45 | $13.58 |
52-Week Low | $12.30 | $3.78 |
Enterprise Value | $4.10B | $27.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
AMWL trades at $13.58, up 0.44% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses. Recent news includes a key executive joining Amazon's healthcare unit, potentially opening partnership opportunities.
The outlook is cautiously optimistic as AMWL progresses toward cash-flow breakeven, but persistent net losses and negative margins pose risks. Analyst consensus is mixed, with 33% buy ratings, reflecting uncertainty around profitability timelines amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
